Durveqtix%252525252525252525252525252525252525252525252525252525252525252525252525252525252520gene%252525252525252525252525252525252525252525252525252525252525252525252525252525252520therapy

# Durveqtix gene therapy ## Overview Durveqtix is a gene therapy that delivers a functional copy of the *fVIII* gene to the liver cells. This allows for the production of factor VIII (FVIII) protein, which is deficient in patients with hemophilia A. ## Primary Indications Durveqtix is indicated for the treatment of hemophilia A (congenital factor VIII deficiency) in adult and pediatric patients aged 12 years and older who have severe or moderately severe hemophilia A. ## Adult Dosing The recommended dose of Durveqtix is a single intravenous infusion of 6 x 10¹³ vector genomes (vg) per kilogram of body weight. ## Pediatric Dosing The recommended dose of Durveqtix for pediatric patients aged 12 years and older is a single intravenous infusion of 6 x 10¹³ vector genomes (vg) per kilogram of body weight. Dosing has not been established in pediatric patients younger than 12 years. ## Dose Adjustments No dose adjustments are required based on renal or hepatic impairment. ## Contraindications Durveqtix is contraindicated in patients with known hypersensitivity to any of its components or to the adeno-associated virus (AAV) vector. ## Adverse Effects The most common adverse reactions observed in clinical trials included: * Elevated alanine aminotransferase (ALT) * Elevated aspartate aminotransferase (AST) * Infusion-related reactions (e.g., headache, fatigue, nausea, back pain) * Hepatitis Serious adverse reactions can include anaphylaxis and liver enzyme elevations. Patients should be monitored for signs of hypersensitivity and hepatotoxicity. ## Key Drug Interactions Corticosteroids: Concomitant use of corticosteroids may increase the risk of liver enzyme elevations. If used concurrently, careful monitoring of liver function is recommended. Immunosuppressants: The long-term effects of co-administration with immunosuppressants are unknown. ## Monitoring * **Liver Function Tests (LFTs):** Monitor ALT, AST, bilirubin, and alkaline phosphatase at baseline and regularly for at least 6 months after infusion. * **FVIII Activity:** Monitor FVIII activity levels to assess efficacy and guide treatment decisions for breakthrough bleeding or surgical procedures. * **Signs of Hypersensitivity:** Monitor for signs and symptoms of anaphylaxis during and after infusion. ## Clinical Pearls * Durveqtix is a one-time infusion. * Patients should be screened for pre-existing anti-AAV antibodies, although the impact of pre-existing antibodies on efficacy and safety is not fully characterized. * Following infusion, patients should be managed by a hemophilia treatment center. **Disclaimer:** This information is intended for clinical use and does not replace the official prescribing information. Always consult the most current product monograph and local protocols for complete and up-to-date guidance.